Scientists hunt for biomarkers to personalize cancer therapy
NCT ID NCT00628368
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study analyzed tumor and blood samples from 160 people with esophageal or rectal cancer. Researchers looked for genetic markers in the EGFR signaling pathway that might predict how well a patient responds to chemoradiotherapy given before surgery. The goal is to better understand which patients benefit most from this treatment approach.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which patients will respond well to chemoradiotherapy, leading to more personalized treatment plans.
- What could go wrong
- This is an observational, lab-based study, not a treatment trial. The findings may not translate into immediate clinical changes or benefit participants directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
160 people
The number who actually took part.
- Started
-
Nov 2005
- Finished
-
Sep 2009
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 120 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or rectum * Planning to receive neoadjuvant treatment, including radiotherapy or chemoradiotherapy PATIENT CHARACTERISTICS: * Not pregnant or nursing * No blood disorder * Not deprived of freedom or protected by law PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, 34298, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- Blood proteins may predict who beats esophageal cancer with chemoradiation
- A 2.2 mm scope could spot cancerous tissue in minutes, not days
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in